Novavax is part of the FDA’s COVID-19 booster debate, but its vaccine still hasn’t been authorized
Novavax’s NVAX, -0.81% COVID-19 vaccine candidate played a front-and-center role during this week’s debate about how best to update the …
Novavax’s NVAX, -0.81% COVID-19 vaccine candidate played a front-and-center role during this week’s debate about how best to update the …
Scattered outbreaks of monkeypox cases have been raising alarm, and there are plenty of questions about how people can protect …
Hi, MarketWatchers. Don’t miss these top stories. ‘I chose to take a gamble’: Husband-wife lab researchers admit taking Pfizer vaccine …
The Centers for Disease Control and Prevention is expected to announce later Friday a loosening of federal face-mask requirements that …
Moderna said Thursday it expects COVID-19 to become endemic in 2023, meaning it will be another seasonal disease that can …
Did anyone actually give a 50-year-old federal agency — the government’s Occupational Safety and Health Administration — the legal ability …
You have a blistering headache. Your body aches. You’ve developed a cough. You’re sneezing. But you test negative on an …
I’m not sure this is a question for the Moneyist, but here goes. I’m 34, I live alone, and I …
It’s easy to point the finger. This week, U.S. health officials reduced isolation times for Americans who test positive for …
The omicron variant of the coronavirus that causes COVID-19 evades immunity from past infection or from two doses of a …